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Coenzyme B12 dependent reactions play a key role in the metabolism of humans and 
many other life forms. We describe a bio-inspired semi-artificial adenosylpeptide B12 
that behaves as cofactor in B12-dependent enzymatic reactions of glutamate mutase 
from Clostridium cochlearium and of ribonucleotide reductase from Lactobacillus 
delbrueckii. It is demonstrated that the peptide backbone influences the chemical 
properties of the artificial adenosylcobalamin cofactor and modulates the bioactivity 
in vitro and in vivo. In addition, inhibition of bacterial growth of L. delbrueckii is 
demonstrated with an IC50 value of 2 µM after ten hours, providing a potentially 
powerful approach for the development of antibacterial and antiproliferative 
compounds with a novel mode-of-action. 
  
Organometallic compounds have gained considerable attention for medical 
purposes.[1-3] Rationally designed metal complexes can competitively bind to a 
protein-binding pocket and effectively inhibit enzymatic function.[4-8] 
The development of RuII-metal complexes as potent and selective kinase inhibitors 
are probably the most prominent current examples.[9] In contrast to fully synthetic 
enzyme inhibitors, rather little attention is paid to the development of structurally 
perfect, but catalytically inactive surrogates of essential cofactor catalysts. The 
cofactors methylcobalamin (MetCbl) and adenosylcobalamin (AdoCbl) have been 
considered for long time the only organometallic compounds in biological systems 
and they are essential for the metabolism of humans and many other life-forms.[10] 
MetCbl-dependent methionine synthase (MetH) is the only human enzyme able to 
convert 5-methyltetrahydrofolate to unsubstituted tetrahydrofolate required for purine 
and pyrimidine biosyntheses in humans, whereas AdoCbl-dependent ribonucleotide 
reductase (RNR) is essential for DNA replication in certain microorganisms.[11] 
In our efforts to develop anti-vitamins as inhibitors of vitamin B12-dependent 
enzymes,[12-14] we report the coordination chemistry and bioactivity of an organo-
metallic peptide B12 cofactor (1+, Scheme 1). We envisaged that an artificial biomi-
metic peptide backbone replacing the Į-ribazole linker at the “lower” face of the 
corrin macrocycle would strongly modulate the ‘base on/ base off’ equilibrium of the 
artificial cofactor and thereby affect enzymatic catalysis in both, the ‘base on’ as well 
as ‘base off/ histidine on’ constitutions (Figure 1).[14-17] Adenosylpeptide B12 (Ado-
pB12; 1+) was synthesized from pB12 (3+)[14] and 5'-chloro-5'-deoxyadenosine under 
reductive conditions (Scheme 2),[18-20] isolated by preparative reverse phase C18 
chromatography and analyzed by UV-Vis, 1H-NMR and MS spectrometry. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic model for the binding of the semi-artificial adenosylpeptide B12 
cofactor to enzymes in either the ‘base on’ (A) or ‘base off/ histidine on’ constitution 
(B). The structurally modified backbone and the unaltered adenosyl moiety of the 
cofactor are shown in blue and grey and the enzymes are depicted green. 
 
 

In the high-resolution mass spectrum of 1+, a signal at m/z 734.34579 (m/zcalc 
734.34496) corresponding to [1++H]2+ ions with the molecular formula of 
C70H97CoN20O12 was observed.  
The “unique” UV-Vis spectrum of 1 (1: 1+ x CF3COO-; Figure 2) with one broad 
absorption for the Į/ȕ-bands is comparable to the absorption spectra of 2 in the ‘base 
on’ form.[21] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Temperature dependent UV-Vis spectra of 1 (18 ȝM; Britton-Robinson buffer18, pH 
7.5; T= 0-90°C). The absorption values at 517 nm have been used for calculating Tmid ([1+]/ 
[1+off] = 1) = 65°C by Boltzmann simulation (Figure S2). 
 
 
Spectrophotometric pH titrations of 1 revealed a pKbase off value of 4.4 (Figure 
S1),[18] indicating that the ‘base on’ form is eight times less favored compared to 2 
(pKbase off = 3.5).[22] Dissociation of the 5,6-dimethylbenzimidazole (Dmbz) base from 
the CoIII centre was also observed with temperature dependent UV-Vis experiments at 
pH 7.5 (Figure 2) indicating a Gibbs energy of -6.6 kJ/mol as outlined in the 
Supporting Information.23 This value is slightly higher than that of 2 (ǻG0 = -10.8 
kJ/mol24). The corresponding enthalpy (ǻH0) and entropy (ǻS0) values are -49.7 
kJ/mol and -147 J/Kmol, respectively.[18] A correlation between the pKbase off and the 
ǻH0 and ǻS0 values is observed (Figure 3). 
This trend is underscored by comparison with the thermodynamic values of other 
alkylcobalamins having either different carbon-based ligands (5-8) or a modified Į-
ribazole backbone (9) (for structures of 5-9 see Figure S3).[18, 23, 25-27] The impact of 
the malfunctioning ‘base on/ base off’ trigger of the artificial cofactor on the 
bioactivity was studied with the microorganism L. delbrueckii and the enzyme 
glutamate mutase from Clostridium cochlearium. The former requires ‘base on’ 
adenosylcobalamin (2) as cofactor for RNR as the only B12-dependent enzyme 
(Figure 1 A),[28] whereas the Dmbz base of 2 is substituted with a histidine side chain 

of the protein (‘base off/ histidine on’) in the active site of glutamate mutase (Figure 1 
B).[29] The ‘loop’ consisting of propanolamine, phosphate, ribose and Dmbz sits in a 
pocket of component S. AdoCbl-dependent glutamate mutase triggers the reversible 
radical rearrangement between (S)-glutamate and (2S,3S)-3-methylaspartate (Table 
1).[30] 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Structural formula of Ado-pB12 (1+), AdoCbl (2), pB12 (3+), and B12 (4). The 
artificial and natural loop structures are shown in blue.  
 
 
 
 
 
 
 
Scheme 2. Synthesis of the artificial cofactor. Ado-pB12 (1+) was synthesized from 3+. The 
counter-ions are CF3COO-.18  
 
The activity of glutamate mutase was determined in a standard coupled assay at two 
different ratios of the protein components GlmS and GlmE (S:E = 2 or 14) with either 
1 or 2 as cofactor.[31] Similar apparent Km values for 1 and 2 suggest equal affinities 
of the cofactors to the enzyme and indicate that both cofactors were able to 
reconstitute hologlutamate mutase from GlmS and E. The catalytic efficiency 
(kcat/Km, s-1M-1) of 1, however, was approximately 10 times reduced as compared to 

that of 2 (Table 1). This is probably caused by a slightly tilted or kinked binding of 
the dissociated, artificial peptide loop to subunit S of the protein.[32] 
 B12-dependent cell growth studies with L. delbrueckii were conducted to gain insights 
into the in vivo activity of pB12 (3). A strongly reduced, yet residual concentration 
dependent bioactivity of 3 was observed (Figure 4, lower part). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Plot of the pKbase off values of various alkyl-cobalamins vs their entropy and enthalpy 
values.13, 17, 18, 20, 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Solid circles: Concentration dependence of the bioactivity of pB12 (3) at 37°C (n=3) 
after 10 hours. Hollow circles: Inhibition of the bioactivity of vitamin B12 (4, 0.2 nM) by pB12 
(3, concentrations ranging from 0.2 nM to 2 µM) at 37°C (n=3) after 10 hours (10 hours = 
maximum growth rate in the exponential phase; ǻ OD660: the net absorption of the samples 
at 660 nm compared to the blank measurement). 
  

 This behaviour gives evidence that the microorganism still recognizes, internalizes 
and metabolizes 3+ into its organometallic analog 1+.[13] The artificial cofactor is still 
catalytically active in the ‘base on’ constitution with an apparent Km of ca. 2 µM 
(Figure 4). 
Competition experiments with B12 (4, 0.25 ng/ml) and increasing amounts of 3 (1-
10000 eq.) revealed an IC50 value of 2 µM after 10 h. Under these conditions, 
bacterial growth depends apparently solely on the reduced bioactivity of 3 (Figure 4, 
upper part versus lower part). The degree of inhibition is time dependent and 
decreases from 60% after 6 h (onset exponential phase) to around 20% after 24 h 
(stationary phase), most likely due to the replacement of 1+ with 2 (Figure S4).[18] 
 
Table 1. Kinetic constants of 1 and 2 in the reaction catalyzed by partially purified glutamate 
mutase from Clostridium cochlearium at different ratios of components S and E. The 
rearrangement is initiated by abstraction of HSi by the 5'-deoxyadenosyl radical from C4 of 
glutamate. 
.  
 apparent Km [µM] kcat [s-1] kcat / Km x 10-6 [s-1M-1] 
GlmS:GlmE 14 2 14 2 14 2 
1 0.35±0.05 1.07±0.04 0.09±0.01 0.12±0.01 0.26 0.11 
2 0.52±0.06 1.12±0.04 1.24±0.36 1.24±0.36 2.38 1.10 
 
 Although the two systems are not directly comparable, we attribute the apparent 
lowered activity of 3+ in vivo compared to the in vitro activity of 1+ to the complex (i) 
bacterial uptake and (ii) metabolism to the organometallic cofactor 1+. Intuitively, it is 
reasonable that (iii) the requirement of a ‘base on’ constitution of the cofactor in RNR – 
in contrast to the ‘base off’constitution in glutamate mutase – affects enzymatic much 
more strongly. The Dmbz base of the peptide backbone is coordinated to the cobalt 
center and directly influences the trans-located cobalt-carbon bond of the artificial 
cofactor. 
    Some modified B12 derivatives have already been tested as anti-vitamins in 
pioneering studies[33, 34] or have been applied as probes in enzymatic reactions.[32, 35-38]  
    Here we used for the first time an artificial cofactor with a biomimetic peptide 
backbone, studied its intramolecular coordination chemistry and demonstrated reduced 
catalytic efficiencies in both, the ‘base on’ and ‘base off/ histidine on’ constitutions. 
    The inhibitory potential of peptide B12s is useful for the development of novel 
antibacterial and antiproliferative agents. 
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